- Home
- API vs AUTL Comparison
API vs AUTL Comparison
Compare API & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | API | AUTL |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 386.2M | 407.2M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | API | AUTL |
|---|---|---|
| Price | $4.01 | $1.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 275.8K | ★ 1.3M |
| Earning Date | 05-26-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $13.46 | $80.32 |
| Revenue Next Year | $12.87 | $53.96 |
| P/E Ratio | $92.30 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $3.14 | $1.18 |
| 52 Week High | $5.15 | $2.70 |
Technical Indicators
Market Signals| Indicator | API | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 63.00 | 65.05 |
| Support Level | $4.01 | $1.65 |
| Resistance Level | $5.12 | $1.80 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 91.56 | 90.28 |
Price Performance
Historical ComparisonAbout API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.